MapLight Therapeutics, Inc. vs Maravai LifeSciences Holdings, — Valuation Comparison 2026
Access all valuation models for MPLT vs MRVI — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.
Access Full Analysis — From $27/mo →MRVI scores higher with a 6.4/10 quality rating vs MPLT's 5.0/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.
Comparing MapLight Therapeutics, Inc. (MPLT) and Maravai LifeSciences Holdings, (MRVI) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.
MPLT currently trades at $29.78 with a QOC of 5.0/10, while MRVI trades at $4.64 with a QOC of 6.4/10.
Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).